203 related articles for article (PubMed ID: 30642912)
1. Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy.
Gounder MM; Zhu G; Roshal L; Lis E; Daigle SR; Blakemore SJ; Michaud NR; Hameed M; Hollmann TJ
Clin Cancer Res; 2019 Apr; 25(7):2064-2071. PubMed ID: 30642912
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
3. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers.
Forrest SJ; Al-Ibraheemi A; Doan D; Ward A; Clinton CM; Putra J; Pinches RS; Kadoch C; Chi SN; DuBois SG; Leavey PJ; LeBoeuf NR; Mullen E; Collins N; Church AJ; Janeway KA
Clin Cancer Res; 2020 Jun; 26(12):2882-2890. PubMed ID: 32122923
[TBL] [Abstract][Full Text] [Related]
4. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
5. Rapid and Complete Response to Combination Anti-CTLA-4 and Anti-PD-1 Checkpoint Inhibitor Therapy in a Patient With Stage IV Refractory End-stage Epithelioid Sarcoma: A Case Report.
Pecora A; Halpern S; Weber M; Paleoudis EG; Panush D; Patterson F; Toretsky J
J Immunother; 2020; 43(9):286-290. PubMed ID: 32815894
[TBL] [Abstract][Full Text] [Related]
6. Poorly differentiated chordoma showing loss of SMARCB1/INI1: Clinicopathological and radiological spectrum of nine cases, including uncommon features of a relatively under-recognized entity.
Rekhi B; Michal M; Ergen FB; Roy P; Puls F; Haugland HK; Soylemezoglu F; Kosemehmetoglu K
Ann Diagn Pathol; 2021 Dec; 55():151809. PubMed ID: 34482218
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
8. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
Qi L; Lindsay H; Kogiso M; Du Y; Braun FK; Zhang H; Guo L; Zhao S; Injac SG; Baxter PA; Su JM; Xiao S; Erickson SW; Earley EJ; Teicher B; Smith MA; Li XN
Lab Invest; 2022 Feb; 102(2):185-193. PubMed ID: 34802040
[TBL] [Abstract][Full Text] [Related]
9. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
[TBL] [Abstract][Full Text] [Related]
10. [Poorly-differentiated chordoma with INI1 loss: a clinicopathologic study].
Feng JY; Chen L; Ma YY; Yang HW; Chen L
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):695-698. PubMed ID: 29050071
[No Abstract] [Full Text] [Related]
11. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
12. Poorly differentiated chordoma with loss of SMARCB1/INI1 expression in pediatric patients: A report of two cases and review of the literature.
Cha YJ; Hong CK; Kim DS; Lee SK; Park HJ; Kim SH
Neuropathology; 2018 Feb; 38(1):47-53. PubMed ID: 28812319
[TBL] [Abstract][Full Text] [Related]
13. Targeting epigenetics in sarcomas through EZH2 inhibition.
Italiano A
J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
[TBL] [Abstract][Full Text] [Related]
14. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
[TBL] [Abstract][Full Text] [Related]
15. SMARCB1/INI1 Involvement in Pediatric Chordoma: A Mutational and Immunohistochemical Analysis.
Antonelli M; Raso A; Mascelli S; Gessi M; Nozza P; Coli A; Gardiman MP; Arcella A; Massimino M; Buttarelli FR; Giangaspero F
Am J Surg Pathol; 2017 Jan; 41(1):56-61. PubMed ID: 27635948
[TBL] [Abstract][Full Text] [Related]
16. Loss of SMARCB1/INI1 expression in poorly differentiated chordomas.
Mobley BC; McKenney JK; Bangs CD; Callahan K; Yeom KW; Schneppenheim R; Hayden MG; Cherry AM; Gokden M; Edwards MS; Fisher PG; Vogel H
Acta Neuropathol; 2010 Dec; 120(6):745-53. PubMed ID: 21057957
[TBL] [Abstract][Full Text] [Related]
17. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
[TBL] [Abstract][Full Text] [Related]
18. Poorly differentiated chordoma with whole-genome doubling evolving from a SMARCB1-deficient conventional chordoma: A case report.
Curcio C; Cimera R; Aryeequaye R; Rao M; Fabbri N; Zhang Y; Hameed M
Genes Chromosomes Cancer; 2021 Jan; 60(1):43-48. PubMed ID: 32920865
[TBL] [Abstract][Full Text] [Related]
19. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; de Stanchina E; Dela Cruz FS; Kung AL; Gounder MM; Kentsis A
Cancer Discov; 2024 Jun; 14(6):965-981. PubMed ID: 38315003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
